

Secrétariat scientifique

Publications COL 2022

Boria, F ; Chiva, L ; Chacon, E ; Zanagnolo, V ; Fagotti, A ; Kucukmetin, A & al. *SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer.* **Int J Gynecol Cancer**, 2022, 32, 1236-1243

Cleret, D ; Gradwohl, M ; Dekerle, L ; Drucbert, AS ; Idziorek, T ; Pasquier, D & al. *Preclinical Study of Radiation on Fat Flap Regeneration under Tissue-engineering Chamber: Potential Consequences for Breast Reconstruction.* **Plast Reconstr Surg Glob Open**, 2022, 10, e4720

Spira, A ; Awada, A ; Isambert, N ; Lorente, D ; Penel, N ; Zhang, Y & al. *Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase I trial in patients with advanced triple-negative breast cancer.* **Front Oncol**, 2022, 12, 981940

Ferrari, A ; Gatz, SA ; Minard-Colin, V ; Alaggio, R ; Hovsepyan, S ; Orbach, D & al. *Shedding a Light on the Challenges of Adolescents and Young Adults with Rhabdomyosarcoma.* **Cancers (Basel)**, 2022, 14, 6060

Cordoba, A ; Durand, B ; Escande, A ; Taieb, S ; Amor, MBH ; Le Deley, MC & al. *Prognostic impact of tumor size reduction assessed by magnetic resonance imaging after radiochemotherapy in patients with locally advanced cervical cancer.* **Front Oncol**, 2022, 12, 1046087

Bruand, M ; Salleron, J ; Guihard, S ; Crety, CM ; Liem, X ; Pasquier, D & al. *Acute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort.* **BMC Cancer**, 2022, 22, 1318

Cherifi, F ; Lefevre Arbogast, S ; Font, J ; Abdeddaim, C ; Becourt, S ; Penel, N & al. *The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer.* **Front Oncol**, 2022, 12, 1049970

Carausu, M ; Carton, M ; Diéras, V ; Petit, T ; Guiu, S ; Gonçalves, A & al. *Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.* **JAMA Netw Open**, 2022, 5,

e2247154

Cren, PY ; Penel, N ; Cordoba, A ; Decanter, G ; Gaboriau, L ; Ben Haj Amor, M. *Myositis ossificans circumscripta after surgery and radiotherapy and during sunitinib treatment: a case report*. **J Med Case Rep**, 2022, 16, 454

Gaggero, S ; Martinez-Fabregas, J ; Cozzani, A ; Fyfe, PK ; Leprohon, M ; Yang, J & al. *IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein*. **Sci Immunol**, 2022, 7, eade5686

Hudry, D ; Le Guellec, S ; Meignan, S ; Bécourt, S ; Pasquesoone, C ; El Hajj, H & al. *Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints*. **Cancers (Basel)**, 2022, 14, 5332

Ghannam, Y ; Di Meglio, A ; Sarrade, T ; Jacquet, A ; Everhard, S ; Kirova, Y & al. *Impact of radiation therapy on fatigue at 1 year in breast cancer survivors in the prospective multicentre CANcer TOxicity cohort*. **Eur J Cancer**, 2022, 177, 143-153

Nannini, S ; Penel, N ; Bompas, E ; Willaume, T ; Kurtz, JE ; Gantzer, J. *Shortening the Time Interval for the Referral of Patients With Soft Tissue Sarcoma to Expert Centers Using Mobile Health: Retrospective Study*. **JMIR Mhealth Uhealth**, 2022, 10, e40718

Sturdza, AE ; Stephanides, M ; Jurgenliemk-Schulz, I ; Eriksen, JG ; Benstead, K ; Hoskin, P & al. *Brachytherapy training survey among radiation oncology residents in Europe*. **Radiother Oncol**, 2022, 177, 172-178

Duroux-Richard, I ; Gagez, AL ; Alaterre, E ; Letestu, R ; Khalifa, O ; Jorgensen, C & al. *miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study*. **Front Immunol**, 2022, 13, 983771

Da Silva, A ; Fléchon, A ; Coquan, E ; Planchamp, F ; Culine, S ; Murez, T & al. *How to improve adherence of guidelines for localized testicular cancer surveillance: A Delphi consensus study*. **Front Oncol**, 2022, 12, 1036190

Cherifi, F ; Da Silva, A ; Johnson, A ; Blanc-Fournier, C ; Abramovici, O ; Broyelle, A & al. *HELENA:*

HER2-Low as a predictive factor of response to Neoadjuvant chemotherapy in early breast cancer. **BMC Cancer**, 2022, 22, 1081

Terrassoux, L ; Claux, H ; Bacari, S ; Meignan, S ; Furlan, A. *A Bloody Conspiracy- Blood Vessels and Immune Cells in the Tumor Microenvironment.* **Cancers (Basel)**, 2022, 14, 4581

Geyer, CE ; Garber, JE ; Gelber, RD ; Yothers, G ; Taboada, M ; Ross, L & al. *Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.* **Ann Oncol**, 2022, 33, 1250-1268

Zilli, T ; Achard, V ; Dal Pra, A ; Schmidt-Hegemann, N ; Jerezek-Fossa, BA ; Lancia, A & al. *Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus.* **Radiother Oncol**, 2022, 176, 199-207

Jacot, W ; Lusque, A ; Vicier, C ; Mailliez, A ; de La Motte Rouge, T ; Cabel, L & al. *Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.* **Br J Cancer**, 2022, 127, 1963-1973

Christophe, V ; Anota, A ; Vanlemmens, L ; Cortot, A ; Ceban, T ; Piessen, G & al. *Unmet supportive care needs of caregivers according to medical settings of cancer patients: a cross-sectional study.* **Support Care Cancer**, 2022, 30, 9411-9419

Houvenaeghel, G ; de Nonneville, A ; Cohen, M ; Classe, JM ; Reyat, F ; Mazouni, C & al. *Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study.* **Eur J Cancer**, 2022, 176, 58-69

Gouin, F ; Stoeckle, E ; Honoré, C ; Ropars, M ; Jafari, M ; Mattei, JC & al. *Overall survival in patients with re-excision of positive microscopic margins of limb and trunk wall soft tissue sarcoma operated outside of a reference center: a nationwide cohort analysis.* **BMC Cancer**, 2022, 22, 1034

Blay, JY ; Duffaud, F ; George, S ; Maki, RG ; Penel, N. *Regorafenib for the Treatment of Sarcoma.* **Curr Treat Options Oncol**, 2022, 23, 1477-1502

Mallebranche, C ; Reguerre, Y ; Fresneau, B ; Andre, N ; Berger, C ; Briandet, C & al. *The French*

FRACTURE database: A way to improve knowledge on management of children with very rare tumors. **Pediatr Blood Cancer**, 2022, 69, e30003

Marec-Berard, P ; Lervat, C ; Riberon, C ; Laurence, V. [*Go-AJA: Ten years of actions dedicated to adolescent and young adult cancer patients*]. **Bull Cancer**, 2022, 109, 985-987

Debaudringhien, M ; Blay, JY ; Bimbai, AM ; Bonvalot, S ; Italiano, A ; Rousset-Jablonski, C & al. *Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis.* **ESMO Open**, 2022, 7, 100578

de Calbiac, O ; Lusque, A ; Mailliez, A ; Bachelot, T ; Uwer, L ; Mouret-Reynier, MA & al. *Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.* **JAMA Netw Open**, 2022, 5, e2231170

Coudert, V ; Penel, N ; Le Deley, MC ; Forestier, A. [*Expertise for management of immune-related adverse events in cancer therapy: Mapping of French practicing*]. **Bull Cancer**, 2022, 109, 1217-1226

Haaser, T ; Constantinides, Y ; Lahmi, L ; Huguet, F ; de Crevoisier, R ; Dejean, C & al. [*Crisis situations: Ethical reflection on prioritization of care access in radiation oncology*]. **Cancer Radiother**, 2022, 26, 834-840

Ninni, S ; Gallot-Lavallée, T ; Klein, C ; Longère, B ; Brigadeau, F ; Potelle, C & al. *Stereotactic Radioablation for Ventricular Tachycardia in the Setting of Electrical Storm.* **Circ Arrhythm Electrophysiol**, 2022, 15, e010955

Andre, F ; Filleron, T ; Kamal, M ; Mosele, F ; Arnedos, M ; Dalenc, F & al. *Genomics to select treatment for patients with metastatic breast cancer.* **Nature**, 2022, 610, 343-348

Jouglar, E ; Laprie, A ; Isfan, F ; Dumont, B ; Thebaud, E ; Escande, A & al. *Locoregional failure after postoperative flank irradiation for nephroblastoma: Results from the French cohort of the SIOP-2001 trial.* **Pediatr Blood Cancer**, 2022, 69, e29950

Vilotte, F ; Pasquier, D ; Blanchard, P ; Supiot, S ; Khalifa, J ; Schick, U & al. *Recommendations for stereotactic body radiation therapy for spine and non-spine bone metastases. A GETUG (French society of urological radiation oncologists) consensus using a national two-round modified Delphi survey.* **Clin Transl**

Radiat Oncol, 2022, 37, 33-40

Michalet, M ; Riou, O ; Azria, D ; Decoene, C ; Crop, F. *News in magnetic resonance imaging use for radiation oncology*. **Cancer Radiother**, 2022, 26, 784-788

Bini, M ; Quesada, S ; Meeus, P ; Rodrigues, M ; Leblanc, E ; Floquet, A & al. *Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database*. **Cancers (Basel)**, 2022, 14, 4040

Roquette, I ; Bogart, E ; Lacornerie, T ; Ningarhari, M ; Bibault, JE ; Le Deley, MC & al. *Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety*. **Cancers (Basel)**, 2022, 14, 3892

Goldrat, O ; De Cooman, M ; Mailliez, A ; Delbaere, A ; D'Orazio, E ; Demeestere, I & al. *Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study*. **Eur J Cancer**, 2022, 174, 134-141

Peters, S ; Dziadziuszko, R ; Morabito, A ; Felip, E ; Gadgeel, SM ; Cheema, P & al. *Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial*. **Nat Med**, 2022, 28, 1831-1839

Chargari, C ; Escande, A ; Dupuis, P ; Thariat, J. *Reirradiation: A complex situation*. **Cancer Radiother**, 2022, 26, 911-915

Hudry, D ; Bécourt, S ; Scambia, G ; Fagotti, A. *Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision-a Literature Review*. **Curr Oncol Rep**, 2022, 24, 1661-1668

Martinez-Gomez, C ; Michelas, M ; Scarlata, CM ; Salvioni, A ; Gomez-Roca, C ; Sarradin, V & al. *Circulating Exhausted PD-1⁺CD39⁺ Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade*. **Cancers (Basel)**, 2022, 14, 3679

Vasseur, A ; Carton, M ; Guiu, S ; Augereau, P ; Uwer, L ; Mouret-Reynier, MA & al. *Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study*. **Breast**, 2022, 65, 136-144

Gaye, E ; Penel, N ; Lebellec, L. *Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer)*. **Curr Opin Oncol**, 2022, 34, 570-574

Tanguy, R ; Alapetite, C ; Laprie, A ; Vigneron, C ; Bolle, S ; Wellmant, J & al. *[National meetings for complex cases in pediatric radiation oncology: Back on six years experience]*. **Bull Cancer**, 2022, 109, 1177-1184

Spiereburg, G ; Grimison, P ; Chevreau, C ; Stacchiotti, S ; Piperno-Neumann, S ; Le Cesne, A & al. *Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT*. **Eur J Cancer**, 2022, 173, 219-228

Soldato, D ; Havas, J ; Crane, TE ; Presti, D ; Lapidari, P ; Rassy, N & al. *Coffee and tea consumption, patient-reported, and clinical outcomes in a longitudinal study of patients with breast cancer*. **Cancer**, 2022, 128, 3552-3563

Joly, F ; Fabbro, M ; Berton, D ; Lequesne, J ; Anota, A ; Puszkiel, A & al. *Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study*. **Gynecol Oncol**, 2022, 166, 389-396

Saint-Ghislain, M ; Derrien, AC ; Geoffrois, L ; Gastaud, L ; Lesimple, T ; Negrier, S & al. *MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients*. **Eur J Cancer**, 2022, 173, 105-112

Zola, P ; Ciccone, G ; Piovano, E ; Fuso, L ; Di Cuonzo, D ; Castiglione, A & al. *Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial*. **J Clin Oncol**, 2022, 40, 3817-3827

Shah, MA ; Kojima, T ; Hochhauser, D ; Enzinger, P ; Raimbourg, J ; Hollebecque, A & al. *T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer*. **Future Oncol**, 2022, in press

Pautier, P ; Italiano, A ; Piperno-Neumann, S ; Chevreau, C ; Penel, N ; Firmin, N & al. *Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial*. **Lancet Oncol**, 2022, 23, 1044-1054

Barlesi, F ; Tomasini, P ; Karimi, M ; Michiels, S ; Raimbourg, J ; Daniel, C & al. *Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIRO2-Lung Trial*. **Clin Cancer Res**, 2022, 28, 4018-4026

Chen, TW ; Chiang, RC ; Le Cesne, A ; Hsieh, YC ; Italiano, A ; Yang, YW & al. *Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan*. **Cancer**, 2022, 128, 3360-3369

Crop, F ; Guillaud, O ; Ben Haj Amor, M ; Gaignierre, A ; Barre, C ; Fayard, C & al. *Comparison of compressed sensing and controlled aliasing in parallel imaging acceleration for 3D magnetic resonance imaging for radiotherapy preparation*. **Phys Imaging Radiat Oncol**, 2022, 23, 44-47

El Hajj, H ; Hudry, D ; Gomez, CM ; Boscher, A ; Duchatelet, M ; Leblanc, E & al. *Protected Laparoscopic Large Ovarian Cyst Aspiration: A 5-Step Alternative to Laparotomy*. **J Minim Invasive Gynecol**, 2022, 29, 1038-1039

Hamimed, M ; Leblond, P ; Dumont, A ; Gattaceca, F ; Tresch-Bruneel, E ; Probst, A & al. *Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis*. **Cancer Chemother Pharmacol**, 2022, 90, 29-44

Hajjaji, N ; Lepoutre, K ; Lakhdar, S ; Bécourt, S ; Bellier, C ; Kaczmarek, E & al. *16 Months Follow Up of Patients' Behavior and Mild COVID-19 Patterns in a Large Cohort of Cancer Patients During the Pandemic*. **Front Oncol**, 2022, 12, 901426

Thomassin-Naggara, I ; Ceugnart, L ; Tardivon, A ; Verzaux, L ; Balleyguier, C ; Taourel, P & al. *[French breast cancer screening: What's the place of artificial intelligence?]*. **Bull Cancer**, 2022, 109, 780-785

Conforti, F ; Gronchi, A ; Penel, N ; Jones, RL ; Broto, JM ; Sala, I & al. *Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study*. **Eur J Cancer**, 2022, 171, 183-192

Baker, JL ; Di Meglio, A ; Gbenou, AS ; El Mouhebb, M ; Iyengar, NM ; Michiels, S & al. *Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study*. **Br J Cancer**, 2022, 127, 886-891

Ferrari, A ; Chisholm, JC ; Jenney, M ; Minard-Colin, V ; Orbach, D ; Casanova, M & al. *Adolescents and*

young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study. **Lancet Child Adolesc Health**, 2022, 6, 545-554

Fayet, Y ; Chevreau, C ; Decanter, G ; Dalban, C ; Meeus, P ; Carrère, S & al. *No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks' Outcome?* **Cancers (Basel)**, 2022, 14, 2620

Maio, M ; Ascierto, PA ; Manzyuk, L ; Motola-Kuba, D ; Penel, N ; Cassier, PA & al. *Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.* **Ann Oncol**, 2022, 33, 929-938

Fournier, B ; Hoshino, A ; Bruneau, J ; Bachelet, C ; Fusaro, M ; Klifa, R & al. *Inherited TNFSF9 deficiency causes broad Epstein-Barr virus infection with EBV+ smooth muscle tumors.* **J Exp Med**, 2022, 219, e20211682

Evrard, C ; Aparicio, T ; Soularue, E ; Le Malicot, K ; Desramé, J ; Botsen, D & al. *Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59.* **Biomedicines**, 2022, 10, 1211

Deghaye, M ; Tardivon, A ; Heid, P ; Quertier, MC ; Soler-Michel, P ; Dufour, M & al. *[Digitalization of the French breast cancer screening program].* **Bull Cancer**, 2022, 109, 760-767

Italiano, A ; Bessedé, A ; Pulido, M ; Bompas, E ; Piperno-Neumann, S ; Chevreau, C & al. *Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.* **Nat Med**, 2022, 28, 1199-1206

Bachelot, T ; Cottu, P ; Chabaud, S ; Dalenc, F ; Allouache, D ; Delaloge, S & al. *Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.* **J Clin Oncol**, 2022, 40, 3699-3708

Vano, YA ; Phan, L ; Gravis, G ; Korakis, I ; Schlürmann, F ; Maillet, D & al. *Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.* **Int J Cancer**, 2022, 151, 1335-1344

Ceugnart, L ; Doutriaux-Dumoulin, I ; Heid, P ; Orabona, J ; Deghaye, M ; Dufour, M & al. *[Second reading in breast cancer screening program: State of knowledge and future].* **Bull Cancer**, 2022, 109, 768-779

Roubaud, G ; Özgürö?lu, M ; Penel, N ; Matsubara, N ; Mehra, N ; Kolinsky, MP & al. *Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.* **Eur J Cancer**, 2022, 170, 73-84

Maior, M ; Amonkar, MM ; Norquist, JM ; Ascierto, PA ; Manzyuk, L ; Motola-Kuba, D & al. *Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.* **Eur J Cancer**, 2022, 169, 188-197

Bridoux, M ; Le Deley, MC ; Bertrand, N ; Simon, N ; Sylla, D ; Mirabel, X & al. *Effects of Proton Pump Inhibitors Intake During Chemoradiotherapy for Rectal Cancer: a Retrospective Cohort Study.* **J Gastrointest Cancer**, 2022

Heudel, P ; Frenel, JS ; Dalban, C ; Bazan, F ; Joly, F ; Arnaud, A & al. *Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.* **JAMA Oncol**, 2022, 8, 1001-1009

Baldini, C ; Charton, E ; Schultz, E ; Auroy, L ; Italiano, A ; Robert, M & al. *Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.* **ESMO Open**, 2022, 7, 100468

Mangiardi-Veltin, M ; Sebbag, C ; Rousset-Jablonski, C ; Ray-Coquard, I ; Berkach, C ; Laot, L & al. *Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors.* **Reprod Biomed Online**, 2022, 44, 1031-1044

Allali, S ; Carton, M ; Sarrade, T ; Querel, O ; Jacquet, A ; Rivera, S & al. *CANTO-RT: Skin toxicities evaluation of a multicentre large prospective cohort of irradiated patients for early-stage breast cancer.* **Int J Cancer**, 2022, 151, 1098-1108

Joly, F ; Pasquier, D ; Levy, C ; Mousseau, M ; D'Almeida, MC ; Noal, S & al. *Impact of creative art therapy on fatigue and quality of life in patients treated for localized breast cancer: A randomized study.* **Psychooncology**, 2022, 31, 1412-1419

Brochet, T ; Lapuyade-Lahorgue, J ; Huat, A ; Thureau, S ; Pasquier, D ; Gardin, I & al. *A Quantitative Comparison between Shannon and Tsallis-Havrda-Charvat Entropies Applied to Cancer Outcome Prediction.* **Entropy (Basel)**, 2022, 24, 436

Delannoy, E ; Tellier, G ; Cholet, J ; Leroy, AM ; Treizebré, A ; Soncin, F. *Multi-Layered Human Blood Vessels-on-Chip Design Using Double Viscous Finger Patterning*. **Biomedicines**, 2022, 10, 797

Ninni, S ; Longere, B ; Mirabel, X. *Stereotactic radioablation to treat ventricular tachycardia related to a left ventricular mass*. **Eur Heart J**, 2022, 43, 2341

Di Meglio, A ; Havas, J ; Gbenou, AS ; Martin, E ; El-Mouhebb, M ; Pistilli, B & al. *Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy*. **J Clin Oncol**, 2022, 40, 3190-3204

Charles, C ; Bardet, A ; Larive, A ; Gorwood, P ; Ramoz, N ; Thomas, E & al. *Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France*. **JAMA Netw Open**, 2022, 5, e225118

Rodriguez, D ; Calmon, R ; Aliaga, ES ; Warren, D ; Warmuth-Metz, M ; Jones, C & al. *MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial*. **Radiology**, 2022, 304, 174-182

Descourt, R ; Pérol, M ; Rousseau-Bussac, G ; Planchard, D ; Mennecier, B ; Wislez, M & al. *Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study*. **Cancers (Basel)**, 2022, 14, 1751

Mirjolet, C ; Diallo, I ; Bertaut, A ; Veres, C ; Sargos, P ; Helfre, S & al. *Treatment related factors associated with the risk of breast radio-induced-sarcoma*. **Radiother Oncol**, 2022, 171, 14-21

Rousseau, B ; Bieche, I ; Pasmant, E ; Hamzaoui, N ; Leulliot, N ; Michon, L & al. *PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon*. **Cancer Discov**, 2022, 12, 1435-1448

Gounder, MM ; Razak, AA ; Somaiah, N ; Chawla, S ; Martin-Broto, J ; Grignani, G & al. *Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial*. **J Clin Oncol**, 2022, 40, 2479-2490

Vano, YA ; Elaidi, R ; Bennamoun, M ; Chevreau, C ; Borchiellini, D ; Pannier, D & al. *Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-*

cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. **Lancet Oncol**, 2022, 23, 612-624

Amadeo, B ; Penel, N ; Coindre, JM ; Ray-Coquard, I ; Plouvier, S ; Delafosse, P & al. *Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM)*. **Cancer**, 2022, 128, 2483-2492

Shapira-Frommer, R ; Mileschkin, L ; Manzyuk, L ; Penel, N ; Burge, M ; Piha-Paul, SA & al. *Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study*. **Gynecol Oncol**, 2022, 166, 211-218

Lapierre, A ; Hennequin, C ; Beneux, A ; Belhomme, S ; Benziane Ouaritini, N ; Biston, MC & al. *Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group*. **Crit Rev Oncol Hematol**, 2022, 173, 103661

Daix, M ; Martinez Gomez, C ; Angeles, MA ; Tock, S ; Gladieff, L ; Gabiache, E & al. *Extended pelvic resection for gynecological malignancies: A review of out-of-the-box surgery*. **Gynecol Oncol**, 2022, 165, 393-400

Goy, E ; Tomezak, M ; Facchin, C ; Martin, N ; Bouchaert, E ; Benoit, J & al. *The out-of-field dose in radiation therapy induces delayed tumorigenesis by senescence evasion*. **Elife**, 2022, 11, e67190

Moinard-Butot, F ; Saint-Martin, C ; Pflumio, C ; Carton, M ; Jacot, W ; Cottu, PH & al. *Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort*. **Breast**, 2022, 63, 54-60

Penel, N ; Bonvalot, S ; Bimbai, AM ; Meurgey, A ; Le Loarer, F ; Salas, S & al. *Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis*. **Clin Cancer Res**, 2022, 28, 4105-4111

Chargari, C ; Haie-Meder, C ; Espenel, S ; Garcia, MA ; Ben-Arush, M ; Bolle, S & al. *Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments*. **Int J Radiat Oncol Biol Phys**, 2022, 113, 602-613

Caumette, E ; Di Meglio, A ; Vaz-Luis, I ; Charles, C ; Havas, J ; de Azua, GR & al. *Change in the value of*

work after breast cancer: evidence from a prospective cohort. **J Cancer Surviv**, 2022

Di Meglio, A ; Martin, E ; Crane, TE ; Charles, C ; Barbier, A ; Raynard, B & al. A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design. **Trials**, 2022, 23, 19

Carausu, M ; Carton, M ; Cabel, L ; Patsouris, A ; Levy, C ; Verret, B & al. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. **Ther Adv Med Oncol**, 2022, 14, 17588359221077082

Vauchier, C ; Auclin, E ; Barthélémy, P ; Carril-Ajuria, L ; Ryckewaert, T ; Borchiellini, D & al. REchallenge of NIVolumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study. **J Oncol**, 2022, 2022, 3449660

Jannin, A ; Escande, A ; Al Ghuzlan, A ; Blanchard, P ; Hartl, D ; Chevalier, B & al. Anaplastic Thyroid Carcinoma: An Update. **Cancers (Basel)**, 2022, 14, 1061

Moreau-Bachelard, C ; Champion, L ; Toulmonde, M ; Le Cesne, A ; Brahmi, M ; Italiano, A & al. Patterns of care and outcomes of 417 patients with METastatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG). **ESMO Open**, 2022, 7, 100402

Querleu, D ; Hudry, D ; Narducci, F ; Rychlik, A. Radical Hysterectomy After the LACC Trial: Back to Radical Vaginal Surgery. **Curr Treat Options Oncol**, 2022, 23, 227-239

Penel, N ; Bay, JO. [Cancer research: France facing geopolitical changes and territorial inequality]. **Bull Cancer**, 2022, 109, 247-248

Dalenc, F ; Lusque, A ; De La Motte Rouge, T ; Pistilli, B ; Brain, E ; Pasquier, D & al. Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study. **Eur J Cancer**, 2022, 164, 70-79

Cren, PY ; Chartier, J ; Penel, N ; Huguet, F ; Spano, JP ; Ollivier, L & al. [Feedback on the first three years of application of the reform of the third cycle in oncology]. **Bull Cancer**, 2022, 109, 130-138

Di Meglio, A ; Charles, C ; Martin, E ; Havas, J ; Gbenou, A ; Flaysakier, JD & al. Uptake of

Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer Survivors. **J Natl Compr Canc Netw**, 2022, 20

Doki, Y ; Ajani, JA ; Kato, K ; Xu, J ; Wyrwicz, L ; Motoyama, S & al. *Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.* **N Engl J Med**, 2022, 386, 449-462

Strobbe, G ; Fraipont, F ; Raimbault, S ; Mercier, S ; Stala, T ; Naveau, M & al. *Successful administration of mitotane (O, p''-DDD) in pediatric oncology.* **J Oncol Pharm Pract**, 2022, 28, 1637-1640

Costa, G ; Orbach, D ; Saulpic, J ; Sarda-Thibault, H ; Hanslik, T ; Brethon, B & al. *Varicella post-exposure management for pediatric oncology patients.* **Bull Cancer**, 2022, 109, 287-295

Mallet, A ; Lusque, A ; Levy, C ; Pistilli, B ; Brain, E ; Pasquier, D & al. *Real-world evidence of the management and prognosis of young women (?40?years) with de novo metastatic breast cancer.* **Ther Adv Med Oncol**, 2022, 14, 17588359211070362

Marchais, A ; Marques da Costa, ME ; Job, B ; Abbas, R ; Drubay, D ; Piperno-Neumann, S & al. *Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis.* **Cancer Res**, 2022, 82, 974-985

Poissonnet, V ; Chabrillac, E ; Schultz, P ; Morinière, S ; Gorphe, P ; Baujat, B & al. *Airway management during transoral robotic surgery for head and neck cancers: a French GETTEC group survey.* **Eur Arch Otorhinolaryngol**, 2022, 279, 3619-3627

Sunyach, MP ; Penel, N ; Montané, L ; Cassier, PA ; Largo, AC ; Sargos, P & al. *Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study.* **Radiother Oncol**, 2022, 168, 95-103

Bouaoud, J ; Temam, S ; Galmiche, L ; Cozic, N ; Bolle, S ; Belhous, K & al. *Head and neck Ewing sarcoma: French surgical practice analysis pleads for surgery centralization.* **J Craniomaxillofac Surg**, 2022, 50, 439-448

Di Meglio, A ; Havas, J ; Soldato, D ; Presti, D ; Martin, E ; Pistilli, B & al. *Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.* **J Clin Oncol**, 2022, 40, 1111-1123

Hauteclouque-Rayz, S ; Albert-Thananayagam, M ; Martignene, N ; Le Deley, MC ; Carbonnelle, G ; Penel, N & al. *Long-Term Outcomes and Prognostic Factors of Patients with Metastatic Solid Tumors Admitted to the Intensive Care Unit.* **Oncology**, 2022, 100, 173-181

Overgaard, J ; Aznar, MC ; Bacchus, C ; Coppes, RP ; Deutsch, E ; Georg, D & al. *Personalised radiation therapy taking both the tumour and patient into consideration.* **Radiother Oncol**, 2022, 166, A1-A5

Santana Dos Santos, E ; Spurdle, AB ; Carraro, DM ; Briaux, A ; Southey, M ; Torrezan, G & al. *Value of the loss of heterozygosity to BRCA1 variant classification.* **NPJ Breast Cancer**, 2022, 8, 9

Chacon, E ; Manzour, N ; Zanagnolo, V ; Querleu, D ; Núñez-Córdoba, JM ; Martin-Calvo, N & al. *SUCCOR cone study: conization before radical hysterectomy.* **Int J Gynecol Cancer**, 2022, 32, 117-124

Mailliez, A ; Pigny, P ; Bogart, E ; Keller, L ; D'Orazio, E ; Vanseymortier, M & al. *Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients.* **Int J Cancer**, 2022, 150, 1850-1860

Poirée, M ; Duplan, M ; Letort-Bertrand, M ; Thouvenin, S ; Deparis, M ; Galland, F & al. *[Supportive care in pediatric oncology: Considering children and AYA's special needs].* **Bull Cancer**, 2022, 109, 557-567

Stouvenot, M ; Meurisse, A ; Saint, A ; Buecher, B ; André, T ; Samalin, E & al. *Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Etipopes-HPV01 and Etipopes-HPV02 studies.* **Eur J Cancer**, 2022, 162, 138-147

Baudry, AS ; Yakimova, S ; Congard, A ; Untas, A ; Guiu, S ; Lefeuvre-Plesse, C & al. *Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress.* **Psychooncology**, 2022, 31, 848-855

Bringuiet, M ; Carton, M ; Levy, C ; Patsouris, A ; Pasquier, D ; Debled, M & al. *Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort.* **Breast Cancer Res Treat**, 2022, 191, 577-587

Bay, JO ; Bouleuc, C ; Firmin, N ; Gandemer, V ; Magne, N ; Orbach, D & al. *[A 2021 inventory in oncology news].* **Bull Cancer**, 2022, 109, 8-19

Giovannelli, J ; Pinon, A ; Lenain, M ; Cleys, AL ; Lefebvre, B ; Capon, N & al. *The relationship between social deprivation and a frailty index of cumulative deficits in French middle-aged caregivers.* **BMC Geriatr**, 2022, 22, 15

Escande, A ; Frey, P ; Lacornerie, T ; Mervoyer, E ; Chargari, C ; Laurans, M & al. *Radiotherapy for patient with cardiac implantable electronic device, consensus from French radiation oncology society.* **Cancer Radiother**, 2022, 26, 404-410

Petat, A ; Dansin, E ; Calcagno, F ; Greillier, L ; Pichon, E ; Kerjouan, M & al. *Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network.* **Eur J Cancer**, 2022, 162, 118-127

Chargari, C ; Peignaux, K ; Escande, A ; Renard, S ; Lafond, C ; Petit, A & al. *Radiotherapy for endometrial cancer.* **Cancer Radiother**, 2022, 26, 309-314

de Crevoisier, R ; Supiot, S ; Créhange, G ; Pommier, P ; Latorzeff, I ; Chapet, O & al. *External radiotherapy for prostatic cancers.* **Cancer Radiother**, 2022, 26, 329-343

Chargari, C ; Peignaux, K ; Escande, A ; Renard, S ; Lafond, C ; Petit, A & al. *Radiotherapy of cervical cancer.* **Cancer Radiother**, 2022, 26, 298-308

Créhange, G ; Modesto, A ; Vendrely, V ; Quéro, L ; Mirabel, X ; Rétif, P & al. *Radiotherapy for cancers of the oesophagus, cardia and stomach.* **Cancer Radiother**, 2022, 26, 250-258

Chargari, C ; Peignaux, K ; Escande, A ; Lafond, C ; Peiffert, D ; Petit, A & al. *Role of radiotherapy in the treatment of primary vaginal cancer: Recommendations of the French society for radiation oncology.* **Cancer Radiother**, 2022, 26, 292-297

Hennequin, C ; Belkacémi, Y ; Bourcier, C ; Cowen, D ; Cutuli, B ; Fourquet, A & al. *Radiotherapy of breast cancer.* **Cancer Radiother**, 2022, 26, 221-230

Le Fèvre, C ; Lacornerie, T ; Noël, G ; Antoni, D. *Management of metallic implants in radiotherapy.* **Cancer Radiother**, 2022, 26, 411-416

Escande, A ; Peiffert, D ; Dejean, C ; Hannoun-Lévi, JM ; Cordoba, A ; Pommier, P & al. *Radiotherapy for*

penile cancers. **Cancer Radiother**, 2022, 26, 323-32

Hennequin, C ; Azria, D ; Blanchard, P ; Créhange, G ; Deutsch, É ; Lisbona, A & al. *Specificities of clinical research in radiotherapy*. **Cancer Radiother**, 2022, 26, 104-107

Chargari, C ; Petit, A ; Escande, A ; Peignaux, K ; Lafond, C ; Peiffert, D & al. *Role of radiotherapy in the management of vulvar cancer: Recommendations of the French society for radiation oncology*. **Cancer Radiother**, 2022, 26, 286-291

Dissaux, G ; Josset, S ; Thillays, F ; Lucia, F ; Bourbonne, V ; Pradier, O & al. *Radiotherapy of benign intracranial tumours*. **Cancer Radiother**, 2022, 26, 137-146

Chargari, C ; Giraud, P ; Lacornerie, T ; Cosset, JM. *Prevention of radiation-induced cancers*. **Cancer Radiother**, 2022, 26, 92-95

Morante, L ; El Hajj, H ; Delecourt, C ; Sabiani, L ; Bannier, M ; Rua, S & al. *Superior Hemimastectomy with Inferior Pedicle Nipple-Bearing Flap: A Five-Step Surgical Technique*. **Plast Reconstr Surg**, 2022, 149, 13e-17e

Enault, M ; Minard-Colin, V ; Corradini, N ; Leverger, G ; Thebaud, E ; Rome, A & al. *Extracranial rhabdoid tumours: Results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tissue sarcoma Study Group recommendations*. **Eur J Cancer**, 2022, 161, 64-78

Le Pechoux, C ; Pourel, N ; Barlesi, F ; Lerouge, D ; Antoni, D ; Lamezec, B & al. *Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial*. **Lancet Oncol**, 2022, 23, 104-114

Delebarre, M ; Gonzales, F ; Behal, H ; Tiphaine, A ; Sudour-Bonnange, H ; Lutun, A & al. *Decision-tree derivation and external validation of a new clinical decision rule (DISCERN-FN) to predict the risk of severe infection during febrile neutropenia in children treated for cancer*. **Lancet Child Adolesc Health**, 2022, 6, 260-268

Régis, C ; Le Deley, MC ; Bogart, E ; Leguillet, C ; Boulanger, L ; Chauvet, MP & al. *Functional Cerebral MRI Evaluation of Integration of Breast Reconstruction into the Body Schema*. **Ann Surg Oncol**, 2022, 29,

2652-2661

Delafoy, M ; Verschuur, A ; Scheleirmacher, G ; Tabone, MD ; Sudour-Bonnange, H ; Thébaud, E & al. *High-dose chemotherapy followed by autologous stem cell rescue in Wilms tumors: French report on toxicity and efficacy.* **Pediatr Blood Cancer**, 2022, 69, e29431

Panhaleux, M ; Espitia, O ; Terrier, B ; Manson, G ; Maria, A ; Humbert, S & al. *Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.* **Eur J Cancer**, 2022, 160, 134-139

Bouras, AF ; Decanter, G ; Marin, H ; Bouzid, C ; Gayet, B ; Liddo, G & al. *Postoperative Outcomes After Laparoscopic Liver Resections in Low and High-Volume Centers: A Multicentric Case-Matched Comparative Study.* **World J Surg**, 2022, 46, 362-369

Hamimed, M ; Gattacceca, F ; André, N ; Tresch-Bruneel, E ; Probst, A ; Chastagner, P & al. *Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma.* **Br J Clin Pharmacol**, 2022, 88, 2096-2117

Balaya, V ; Guani, B ; Morice, P ; Querleu, D ; Fourchette, V ; Leblanc, E & al. *Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: A post-hoc analysis of SENTICOL I and SENTICOL II cohorts.* **Gynecol Oncol**, 2022, 164, 53-61

Trédan, O ; Provansal, M ; Abdeddaim, C ; Lardy-Cleaud, A ; Hardy-Bessard, AC ; Kalbacher, E & al. *Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).* **Gynecol Oncol**, 2022, 164, 18-26

Corbaux, P ; Lardy-Cleaud, A ; Alexandre, M ; Fontanilles, M ; Lévy, C ; Viansone, AA & al. *Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.* **Breast Cancer Res Treat**, 2022, 191, 191-207

Hudry, D ; El Hajj, H ; Narducci, F ; Leblanc, E. *Laparoscopic ureteral reimplantation applying the modified psoas hitch and Lich-Gregoir onlay technique: a 10-step surgical video.* **Int Urogynecol J**, 2022, 33, 2577-2579

Boudou-Rouquette, P ; Martin, E ; Kempf, E ; Penel, N ; Toulmonde, M ; Bompas, E & al. *Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group.* **Int J Cancer**, 2022, 150, 825-836

Favier, A ; Boinon, D ; Salviat, F ; Mazouni, C ; De Korvin, B ; Tunon, C & al. *[Surgery or not on an atypical breast lesion? Taking anxiety into account in shared decision support from a prospective cohort of 300 patients].* **Gynecol Obstet Fertil Senol**, 2022, 50, 142-150

Brisset, C ; Carton, M ; Chemin-Airiau, C ; Karanian, M ; Vérité, C ; Corradini, N & al. *Locally aggressive rarely metastasizing tumors and low-grade sarcoma in children, adolescents and young adults: The benefits of a national network.* **Eur J Surg Oncol**, 2022, 48, 508-517

Bensadoun, RJ ; Bollet, MA ; Liem, X ; Cao, K ; Magné, N. *New photobiomodulation device for prevention and cure of radiotherapy-induced oral mucositis and dermatitis: results of the prospective Safe PBM study.* **Support Care Cancer**, 2022, 30, 1569-1577

Illiano, M ; Colinard, M ; Taque, S ; Mallon, B ; Larue, C ; Laithier, V & al. *Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.* **Hepatol Int**, 2022, 16, 125-134

Leleu, T ; Bastit, V ; Doré, M ; Kammerer, E ; Florescu, C ; Alfonsi, M & al. *Histosurgical mapping of endoscopic endonasal surgery of sinonasal tumours to improve radiotherapy guidance.* **Cancer Radiother**, 2022, 26, 440-444

Guigay, J ; Chamorey, E ; Lefebvre, G ; Rotarski, M ; Wagner, JP ; Blot, E & al. *Observational, prospective, phase 4 study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: DIRECT.* **Cancer Rep (Hoboken)**, 2022, 5, e1467

Courade, M ; Bertrand, A ; Guerrini-Rousseau, L ; Pagnier, A ; Levy, D ; Lervat, C & al. *Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study.* **BMJ Support Palliat Care**, 2022, 12, e656-e663